Trials / Completed
CompletedNCT00887861
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Parallel-group Study of BGG492 as Monotherapy in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Investigational new drug, company code: BGG492 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-04-24
- Last updated
- 2017-03-21
Locations
6 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00887861. Inclusion in this directory is not an endorsement.